Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization

被引：6
作者：
El-Agnaf, Moulod R. [1 ]
McCoy, Cathy
Ong, Young-Lee
Eswedi, Abdul-Hakeem
Black, Barbra
Ramadan, Khaled M.
机构：
[1] Ulster Hosp, Dept Hematol, Belfast BT16 1RH, Antrim, North Ireland
[2] Univ British Columbia, St Pauls Hosp, Div Hematol, Providence Hlth Care, Vancouver, BC V5Z 1M9, Canada
来源：
LEUKEMIA & LYMPHOMA | 2007年 / 48卷 / 09期
关键词：
D O I：
10.1080/10428190701509780
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1875 / 1877
页数：3
相关论文
共 15 条
[1]  
[Anonymous], COMM TERM CRIT ADV E
[2]  
AURRANSCHLEINIT.T, 2005, BLOOD S, P106
[3]   Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[4]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[5]   Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy [J].
Dillman, RO .
CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :465-471
[6]  
GHIELMINI M, 2005, BLOOD S, P106
[7]   CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].
Marcus, R ;
Imrie, K ;
Belch, A ;
Cunningham, D ;
Flores, E ;
Catalano, J ;
Solal-Celigny, P ;
Offner, F ;
Walewski, J ;
Raposo, J ;
Jack, A ;
Smith, P .
BLOOD, 2005, 105 (04) :1417-1423
[8]   Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].
McLaughlin, P ;
Grillo-López, AJ ;
Link, BK ;
Levy, R ;
Czuczman, MS ;
Williams, ME ;
Heyman, MR ;
Bence-Bruckler, I ;
White, CA ;
Cabanillas, F ;
Jain, V ;
Ho, AD ;
Lister, J ;
Wey, K ;
Shen, D ;
Dallaire, BK .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833
[9]  
MIDDLETON H, 2005, BLOOD S, P106
[10]   Rapid-infusion rituximab in lymphoma treatment [J].
Provencio, M. ;
Cerdeira, S. ;
Bonilla, F. ;
Sanchez, A. ;
Espana, P. .
ANNALS OF ONCOLOGY, 2006, 17 (06) :1027-U7
12